SEC Form 4 · accession 0001209191-18-062781
ALDER BIOPHARMACEUTICALS INC · ALDR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Carlos Campoy
Officer — Chief Financial Officer
Period of report
Dec 12, 2018
Accepted (ET)
Dec 14, 2018 · 5:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001423824
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $11.50 | Dec 12, 2018 | A | 270,000 | A | — | Dec 11, 2028 | Common Stock | 270,000 | 270,000 | D |
Explanation of responses
- F1The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of December 12, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.